H44AON188 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy3

113. Muscular dystrophy


Clinical trials : 622 Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013762-63-NL
(EUCTR)
16/04/201025/08/2009A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyA phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophy Duchenne Muscular DystrophyProduct Name: PRO044
Product Code: PRO044
INN or Proposed INN: h44AON188
Prosensa Therapeutics B.VNULLNot RecruitingFemale: no
Male: yes
18Phase 1/2Belgium;Netherlands;Italy;Sweden
2EUCTR2009-013762-63-SE
(EUCTR)
19/02/201003/11/2009A study to assess the effect and safety of multiple subcutaneous and intravenous doses of PRO044 in patients with Duchenne DiseaseA phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous and intravenous doses of PRO044 in patients with Duchenne muscular dystrophy Duchenne Muscular Dystrophy
MedDRA version: 14.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: PRO044
Product Code: PRO044
INN or Proposed INN: h44AON188
Prosensa Therapeutics B.VNULLNot RecruitingFemale: no
Male: yes
24Phase 1/2Belgium;Netherlands;Italy;Sweden
3EUCTR2009-013762-63-BE
(EUCTR)
09/12/200903/11/2009A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyA phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophy Duchenne Muscular DystrophyProduct Name: PRO044
Product Code: PRO044
INN or Proposed INN: h44AON188
Prosensa Therapeutics B.VNULLNot RecruitingFemale: no
Male: yes
24Phase 1;Phase 2Belgium;Netherlands;Italy;Sweden